Mereo BioPharma Group

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MREO and other ETFs, options, and stocks.

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649).

CEO

Denise Vera Scots-Knight

CEODenise Vera Scots-Knight

Employees

Employees36

Headquarters

London, Greater London

HeadquartersLondon, Greater London

Founded

2015

Founded2015

Employees

Employees36

MREO Key Statistics

Market cap

256.79M

Market cap256.79M

Price-Earnings ratio

-5.16

Price-Earnings ratio-5.16

Dividend yield

—

Dividend yield—

Average volume

5.99M

Average volume5.99M

High today

$1.78

High today$1.78

Low today

$1.60

Low today$1.60

Open price

$1.73

Open price$1.73

Volume

9.53M

Volume9.53M

52 Week high

$5.02

52 Week high$5.02

52 Week low

$1.58

52 Week low$1.58

MREO News

Benzinga 2d

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday. What Happened? The companies on Wednesday announced th...

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell